Document:

ex10-1

 

Exhibit 10.1

 

COOPERATION AGREEMENT

 

This
Cooperation Agreement (this “Agreement”), effective as of March
4, 2021 (the “Effective
Date”), is entered into by and among Wrap
Technologies, Inc., a Delaware corporation (“Wrap”), Elwood G. Norris
(“Norris”) and
the other persons and entities identified under that certain Norris
Schedule 13D (as defined below) as Reporting Persons (each, a
“Norris Party”
and collectively, the “Norris
Parties”). Wrap and the Norris Parties are together
referred to herein as the “Parties,” and each, a
“Party.” Unless
otherwise defined herein, capitalized terms shall have the meanings
given to them in Section 17 herein.

 

WHEREAS, the Norris Parties beneficially
own 6,452,457 shares of Wrap’s common stock, par value
$0.0001 per share (the “Common Stock”), as of the
Effective Date;

 

WHEREAS, on January 4, 2021, the Norris
Parties submitted to Wrap’s Board of Directors (the
“Board”) a
letter that served as a notice of intent to nominate director
candidates for election and to submit stockholder proposals for
consideration at the 2021 annual meeting of stockholders of Wrap
(the “2021 Annual
Meeting”), which was subsequently supplemented by the
Norris Parties on February 18, 2021 (such supplemented notice
together with the previously submitted notice, the
“Nomination
Notice”);

 

WHEREAS, the Parties have determined
that the interests of Wrap and its stockholders would be best
served by, among other things, avoiding the substantial expense and
duration of a proxy contest;

 

WHEREAS, Wrap and the Norris Parties
desire to enter into this Agreement regarding the addition of two
(2) directors to the Board and certain other matters, as provided
in this Agreement; and

 

WHEREAS, the Norris Parties, among other
things, have agreed to withdraw the Nomination Notice and to
refrain from submitting any director nominations and stockholder
proposals during the Standstill Period (as defined
below).

 

NOW, THEREFORE, in consideration of the
promises, representations and mutual covenants and agreements set
forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows:

 

1. Withdrawal of Nomination
Notice. As of the Effective Date, the Norris Parties hereby
irrevocably agree to take the following actions:

 

(a) immediately and
irrevocably withdraw the Nomination Notice and any other notices
relating to the 2021 Annual Meeting submitted to Wrap in connection
therewith or related thereto and any solicitation materials
concerning the foregoing or otherwise related to the 2021 Annual
Meeting (which they do by their execution of this Agreement) and
not to take any further action in connection with the solicitation
of proxies in connection with the Nomination Notice or any other
notices relating to the 2021 Annual Meeting (other than in
connection with such withdrawal or Section 10 herein); and

 

(b) immediately cease
any and all solicitation and other activities in connection with
the 2021 Annual Meeting (it being understood and agreed that the
Norris Parties are required to vote their own shares of Common
Stock at the 2021 Annual Meeting, subject to the provisions of this
Agreement).

 

 

 

-1-

 

 

2. Board Composition.

 

(a) Board Matters.

 

(i) As soon as
practicable following the Effective Date, (A) the Nominating and
Governance Committee of the Board (the “Nominating Committee”) shall
jointly conduct a search process (the “Joint Search Process”) with the
Norris Parties to choose two (2) new director candidates (each a
“New Director”
and together, the “New
Directors”). The first New Director (or any
Replacement thereof) shall be selected and approved by the
Nominating Committee (with such approval not being unreasonably
withheld) from a set of candidates identified by the Norris Parties
as part of the Joint Search Process, and the second New Director
(or any Replacement thereof) shall be selected and approved by the
Norris Parties (with such approval not being unreasonably withheld)
from a set of candidates identified by the Nominating Committee as
part of the Joint Search Process. The Nominating Committee shall
review the qualifications of the New Directors, each to serve as a
member of the Board and (B) the Board shall determine whether each
New Director is an “Independent Director,” as defined
in The Nasdaq Stock Market LLC Listing Rule 5605 (or applicable
requirement of such other national securities exchange designated
as the primary market on which the Common Stock is listed for
trading) (the “Exchange
Independence Requirement”). In connection with the
foregoing, and as a condition to the nomination or appointment of
each New Director to the Board, each New Director shall (A) be
required to provide to Wrap information required to be, or that is
customarily disclosed by directors or director candidates, in proxy
statements or other filings under applicable law or stock exchange
regulations, information in connection with assessing eligibility,
independence, and other criteria applicable to directors or related
to satisfying compliance and legal obligations, and a fully
completed and executed copy of Wrap’s director candidate
questionnaire (substantially in the form completed by Wrap’s
incumbent non-management directors) and other reasonable and
customary director onboarding documentation (substantially in the
form completed by Wrap’s incumbent non-management directors);
(B) be interviewed by and be reasonably acceptable to the
Nominating Committee and the Board (acting in good faith in
accordance with their customary and generally applicable procedures
for evaluating director candidates); and (C) consent to appropriate
background checks comparable to those undergone by other
non-management directors of Wrap.

 

(ii) Within forty-five
(45) days following the Effective Date (the “Appointment Date”), the Board and
all applicable committees of the Board shall hold meetings and take
all necessary actions to accomplish the following, to (A) increase
the size of the Board’s membership by two (2) director seats
and (B) appoint the New Directors (or any Replacements) (as defined
below) to serve as directors of the Board, with a term beginning
upon such appointment and expiring at the 2021 Annual Meeting or at
such later time when such New Director’s (or any
Replacements) successor is duly elected or appointed in accordance
with Wrap’s Bylaws (as defined below) and applicable
law.

 

(iii) The Board shall
nominate the New Directors (or any Replacements) as candidates for
election to the Board at the 2021 Annual Meeting with a term
expiring at the 2022 annual meeting of stockholders of Wrap (the
“2022 Annual
Meeting”) or at such later time when such New
Director’s successor is duly elected or appointed in
accordance with the Bylaws of Wrap dated March 31, 2017, and as may
be further amended from time to time (the “Bylaws”) and applicable
law.

 

 

 

-2-

 

 

 

(iv) Wrap will include
information about Wrap’s nominees for election to the Board,
including the New Directors (or any Replacement), in Wrap’s
proxy statement filed with the Securities and Exchange Commission
(the “SEC”) in
connection with the 2021 Annual Meeting (the “Proxy Statement”); provided, however, that as a condition to
Wrap’s obligation to nominate each New Director (or any
Replacement) for election at the 2021 Annual Meeting and include
information about each New Director in the Proxy Statement, each
New Director (or any Replacement) shall then be in compliance with
the Company Policies (as defined below).

 

(v) In connection with
the 2021 Annual Meeting and each subsequent annual or special
meeting of stockholders of Wrap that occurs prior to the
Termination Date at which the election of directors is a proposal
for consideration by stockholders, Wrap agrees to recommend,
support and solicit proxies for the election of the New Directors
(or any Replacement) in the same historic manner in which Wrap has
supported its nominees for election at prior annual meetings of
stockholders at which the election of directors was uncontested in
the aggregate, so long as each New Director is then in compliance
with the Company Policies. Wrap agrees that the New Directors (and
any Replacement) shall receive (A) the same benefits of director
and officer insurance as all other non-management directors on the
Board, (B) the same compensation for his or her service as a
director (including service on committees) as the compensation
received by other non-management directors on the Board for regular
service on the Board or committees, according to the Board’s
director compensation policy, and (C) such other benefits on the
same basis as all other non-management directors on the Board,
according to the Board’s director compensation
policy.

 

(b) Board Policies and Procedures.
Each Party acknowledges that the New Directors (and any
Replacement), upon election to the Board, shall be governed by all
of the same policies, processes, procedures, codes, rules,
standards and guidelines applicable to members of the Board,
including, but not limited to, Wrap’s Code of Business
Conduct and Ethics and any other policies on stock ownership,
director resignation, public disclosures and confidentiality
(collectively, the “Company
Policies”), and will be required to adhere to
Wrap’s policies on confidentiality imposed on all members of
the Board.

 

(c) Replacement Rights. If, from
the date on which the New Directors are elected or appointed to the
Board until the Termination Date, either New Director (or any
Replacement) is unable to serve as a director due to (i)
resignation or (ii) death or disability (the “Former Director”), then a
replacement director (a “Replacement”) with relevant
financial and business experience, who qualifies as
“independent” pursuant to the Exchange Independence
Requirement, the SEC rules and regulations, and such Replacement
shall be identified and selected in the same manner in which the
Former Director was identified and selected. The Replacement shall
be expeditiously appointed to the Board, subject to the approval
(not to be unreasonably withheld) by each of the Nominating
Committee and the Board, after conducting a good faith customary
due diligence process and consistent with the Board’s
fiduciary duties (and who satisfies the Company Policies applicable
to all directors). Any Replacement appointed to the Board in
accordance with this Section 2(c) shall be appointed to any
applicable committee of the Board of which the Former Director was
a member immediately prior to such director’s resignation or
removal. In the event that the Nominating Committee determines in
good faith not to appoint any Replacement, then another Replacement
shall be identified and selected in the manner otherwise described
in this Section
2(c).

 

3. Management.

 

(a) Effective no later
than the Effective Date: (i) the Board will appoint incumbent
interim-Chief Executive Officer of Wrap, Thomas P. Smith, as the
Chief Executive Officer of Wrap (“CEO”); and (ii) the Chief
Government Affairs Officer of Wrap shall report directly to, and
take directions from, Mr. Smith immediately upon his appointment as
CEO. Mr. Smith will retain his title as President. As CEO and
President, Mr. Smith will be the most senior executive officer of
the Company and report directly to the Board. The Board will make
no changes to the foregoing actions prior to the time both
vacancies created by the action in Section 2(a)(ii) are filled in
accordance with Section 2(a)(ii) and Section 2(c) (to the extent
applicable); provided that the Board may
make changes if it determines in good faith, after consulting with
outside counsel, that maintaining the status quo would prohibit
Board members from complying with their fiduciary duties as
directors of Wrap to the non-employee, non-Board member
stockholders.

 

(b) Promptly following
the 2021 Annual Meeting, the Board will elect a Chairman of the
Board who meets the Exchange Independence Requirement before and
immediately after such appointment.

 

 

 

-3-

 

 

 

4. Voting.

 

(a) From the Effective
Date until the Termination Date (the “Standstill Period”), each of the
Norris Parties agrees that it will appear in person or by proxy at
each annual or special meeting of stockholders of Wrap (including
any adjournment, postponement, rescheduling or continuation
thereof), whether such meeting is held at a physical location or
virtually by means of remote communications, and will vote (or
execute a consent with respect to) all Voting Securities (as
defined below) beneficially owned by it in accordance with the
Board’s recommendations with respect to (i) each election of
directors, any removal of directors and any replacement of
directors, (ii) the ratification of the appointment of Wrap’s
independent registered public accounting firm, (iii) Wrap’s
“say-on-pay” proposal(s) and (iv) any other proposal to
be submitted to the stockholders of Wrap by either Wrap or any
stockholders of Wrap; provided, however, that each of the
Norris Parties shall be permitted to vote in its discretion on any
proposal of Wrap in respect of any Extraordinary Transaction (as
defined below).

 

5. Mutual
Non-Disparagement.

 

(a) Subject to
Section
7, each Norris
Party agrees that, during the Standstill Period, neither it nor any
of its Representatives (as defined below) shall, and it shall cause
each of its Representatives not to, directly or indirectly, in any
capacity or manner, make, express, transmit, speak, write or
otherwise communicate in any way (or cause, further, assist,
solicit, encourage, support or participate in any of the
foregoing), any remark, comment, message, information, declaration,
communication or other statement of any kind, whether oral, in
writing, electronically transferred or otherwise, that might
reasonably be construed to be derogatory or critical of, or
negative toward, or constitute an ad hominem attack on, or
otherwise disparages, defames or damages the reputation or good
name of Wrap or any of its Representatives, or any of their
businesses, products or services.

 

(b) Wrap hereby
agrees that, during the Standstill Period, neither it nor any of
its Representatives shall, and it shall cause each of its
Representatives not to, directly or indirectly, in any capacity or
manner, make, express, transmit, speak, write or otherwise
communicate in any way (or cause, further, assist, solicit,
encourage, support or participate in any of the foregoing), any
remark, comment, message, information, declaration, communication
or other statement of any kind, whether oral, in writing,
electronically transferred or otherwise, that might reasonably be
construed to be derogatory or critical of, or negative toward, or
constitute an ad hominem attack on, or otherwise disparages,
defames or damages the reputation or good name of any Norris Party
or any of its Representatives, or any of its businesses, products
or services.

 

(c) Notwithstanding the
foregoing, nothing in this Section 5 or elsewhere in this
Agreement shall prohibit any Party from making any statement or
disclosure required under the federal securities laws or other
applicable laws (including to comply with any subpoena or other
legal process from any governmental or regulatory authority with
competent jurisdiction over the relevant Party hereto) or stock
exchange regulations; provided, however, that, unless
prohibited under applicable law, such Party must provide written
notice to the other Party at least one (1) business day prior to
making any such statement or disclosure required under the federal
securities laws or other applicable laws or under stock exchange
regulations or other applicable regulations that would otherwise be
prohibited by the provisions of this Section 5, and reasonably consider any
comments of such other Party.

 

(d) The limitations set
forth in Sections 5(a) and 5(b) shall not prevent any
Party from responding to any public statement made by the other
Party of the nature described in Sections 5(a) and 5(b), if such statement by the
other Party was made in breach of this Agreement.

 

6. No
Litigation.

 

(a) The Norris Parties
covenant and agree that, during the Standstill Period, they shall
not, and shall not permit any of their Representatives to, alone or
in concert with others, knowingly encourage or pursue, or knowingly
assist any other person to threaten, initiate or pursue, any
lawsuit, claim or proceeding (including commencing, encouraging or
supporting any derivative action in the name of Wrap or any class
action against Wrap or any of its officers or directors, in each
case with the intent of circumventing any terms of this Agreement)
before any court or governmental, administrative or regulatory body
(collectively, “Legal
Proceeding”) against Wrap or any of its
Representatives, except for any Legal Proceeding initiated solely
to remedy a breach of or to enforce this Agreement; provided, however, that the foregoing
shall not prevent the Norris Parties or any of their respective
Representatives from responding to oral questions, interrogatories,
requests for information or documents, subpoenas, civil
investigative demands or similar processes (a “Legal Requirement”) in connection
with any Legal Proceeding if such Legal Proceeding has not been
initiated by, or on behalf of, the Norris Parties or any of their
Representatives; provided, further, that in the event that
any of the Norris Parties or any of its Representatives receives
such Legal Requirement, the Norris Parties shall, unless prohibited
by applicable law, give prompt written notice of such Legal
Requirement to Wrap.

 

 

 

-4-

 

 

 

(b) Wrap covenants and
agrees that, during the Standstill Period, it shall not, and shall
not permit any of its Representatives to, alone or in concert with
others, knowingly encourage or pursue, or knowingly assist any
other person to threaten, initiate or pursue, any Legal Proceeding
against any of the Norris Parties or any of its Representatives,
except for any Legal Proceeding initiated solely to remedy a breach
of or to enforce this Agreement; provided, however, that the foregoing
shall not prevent Wrap or any of its Representatives from
responding to a Legal Requirement in connection with any Legal
Proceeding if such Legal Proceeding has not been initiated by, or
on behalf of, Wrap or any of its Representatives; provided, further, that in the event Wrap
or any of its Representatives receives such Legal Requirement, Wrap
shall, unless prohibited by applicable law, give prompt written
notice of such Legal Requirement to the Norris
Parties.

 

7. Standstill.

 

(a) During the
Standstill Period, each Norris Party shall not, and shall cause its
respective Representatives not to, directly or
indirectly:

 

(i) make any
announcement or proposal with respect to, or offer, seek, propose
or indicate an interest in, (A) any form of business combination or
acquisition or other transaction relating to a material amount of
assets or securities of Wrap or any of its subsidiaries, (B) any
form of restructuring, recapitalization or similar transaction with
respect to Wrap or any of its subsidiaries or (C) any form of
tender or exchange offer for shares of Common Stock or other Voting
Securities, whether or not such transaction involves a Change of
Control;

 

(ii) engage in, or
assist in the engagement in, any solicitation of proxies or written
consents to vote any Voting Securities, or conduct, or assist in
the conducting of, any type of binding or nonbinding referendum
with respect to any Voting Securities, or assist or participate in
any other way, directly or indirectly, in any solicitation of
proxies (or written consents) with respect to, or from the holders
of, any Voting Securities, or otherwise become a
“participant” in a “solicitation,” as such
terms are defined in Instruction 3 of Item 4 of Schedule 14A and
Rule 14a-1 of Regulation 14A, respectively, under the Securities
Exchange Act of 1934, as amended, and with the rules and
regulations thereunder (the “Exchange Act”), to vote any
securities of Wrap (including by initiating, encouraging or
participating in any “withhold” or similar
campaign);

 

(iii) purchase or
otherwise acquire, or offer, seek, propose or agree to acquire,
ownership (including beneficial ownership) of any securities of
Wrap, any direct or indirect rights or options to acquire any such
securities, any derivative securities or contracts or instruments
in any way related to the price of shares of Common Stock, or any
assets or liabilities of Wrap; provided, however, that the foregoing
shall not prevent Norris from receiving any securities of Wrap as
compensation for his service as an officer or employee of
Wrap;

 

(iv) advise, encourage
or influence any person with respect to the voting of (or execution
of a written consent in respect of) or disposition of any
securities of Wrap;

 

(v) sell, offer or
agree to sell directly or indirectly, through swap or hedging
transactions or otherwise, the securities of Wrap or any rights
decoupled from the underlying securities held by any of the Norris
Parties to any person not (A) a party to this Agreement, (B) a
member of the Board, (C) an officer of Wrap, or (D) an Affiliate of
any Party (any person not set forth in clauses (A) through (D)
shall be referred to as a “Third Party”) that would knowingly
result in such Third Party, together with its Affiliates, owning,
controlling or otherwise having any beneficial or other ownership
interest representing in the aggregate in excess of 4.9% of the
shares of Common Stock outstanding at such time, except for
Schedule 13G filers that are mutual funds, pension funds, index
funds or investment fund managers that have not been identified on
the most recent “SharkWatch 50” list, as published by
FactSet and any successor (the “SharkWatch List”), are not
publicly disclosed Affiliate funds of such a filer on the
SharkWatch List, or have no known plans to engage in
“shareholder activism”;

 

 

 

-5-

 

 

 

(vi) take any action in
support of or make any proposal or request that constitutes or
would result in: (A) advising, controlling, changing or influencing
any director or the management of Wrap, including, but not limited
to, any plans or proposals to change the number or term of
directors or to fill any vacancies on the Board, except as set
forth in this Agreement, (B) any material change in the
capitalization, stock repurchase programs and practices or dividend
policy of Wrap, (C) any other material change in Wrap’s
management, business or corporate structure, (D) seeking to have
Wrap waive or make amendments or modifications to the Bylaws or the
Amended and Restated Certificate of Incorporation of Wrap dated
March 31, 2017, and as may be further amended from time to time, or
other actions that may impede or facilitate the acquisition of
control of Wrap by any person, (E) causing a class of securities of
Wrap to be delisted from, or to cease to be authorized to be quoted
on, any securities exchange, or (F) causing a class of securities
of Wrap to become eligible for termination of registration pursuant
to Section 12(g)(4) of the Exchange Act;

 

(vii) communicate with
stockholders of Wrap or others pursuant to Rule 14a-1(l)(2)(iv)
under the Exchange Act;

 

(viii) engage in any
course of conduct with the purpose of causing stockholders of Wrap
to vote contrary to the recommendation of the Board on any matter
presented to Wrap’s stockholders for their vote at any
meeting of Wrap’s stockholders or by written
consent;

 

(ix) act, including by
making public announcements or speaking to reporters or members of
the media (whether “on the record” or on
“background” or “off the record”), to seek
to influence Wrap’s stockholders, management or the Board
with respect to Wrap’s policies, operations, balance sheet,
capital allocation, marketing approach, business configuration,
Extraordinary Transactions, or strategy or to obtain representation
on the Board or seek the removal or replacement of any director in
any manner, except as expressly permitted by this
Agreement;

 

(x) call or seek to
call, or request the call of, alone or in concert with others, any
meeting of stockholders, whether or not such a meeting is permitted
by the Bylaws, including a “town hall
meeting”;

 

(xi) deposit any shares
of Common Stock or other Voting Securities in any voting trust or
subject any shares of Common Stock or other Voting Securities to
any arrangement or agreement with respect to the voting of any
shares of Common Stock or Voting Securities (other than any such
voting trust arrangement or agreement solely among the Norris
Parties that is otherwise in accordance with this
Agreement);

 

(xii) seek, or encourage
or advise any person, to submit nominations in furtherance of a
“contested solicitation” for the election, removal or
replacement of directors with respect to Wrap or seek, encourage or
take any other action with respect to the election, removal or
replacement of any directors;

 

(xiii) form, join or in
any other way participate in any “group” (within the
meaning of Section 13(d)(3) of the Exchange Act) with respect to
any Voting Security; provided, however, that the Norris
Parties as disclosed in that certain Schedule 13D, dated January 4,
2021, as amended on February 19, 2021 (together, the
“Norris Schedule 13D”) shall not be
considered a “group” for the purpose of this
Section 7(a)(xiii);
provided,
further, that
nothing herein shall limit the ability of an Affiliate of a Norris
Party to join the “group” disclosed on the Norris
Schedule 13D following the execution of this Agreement, so long as
any such Affiliate agrees in writing to be subject to, and bound
by, the terms and conditions of this Agreement and, if required
under the Exchange Act, files a Schedule 13D or an amendment
thereof, as applicable, within two (2) business days after
disclosing that the Norris Party has formed a group with such
Affiliate;

 

(xiv) demand a copy of
Wrap’s list of stockholders or its other books and records or
make any request pursuant to Rule 14a-7 under the Exchange Act or
under any statutory or regulatory provisions of the State of
Delaware providing for stockholder access to books and records
(including lists of stockholders) of Wrap;

 

 

 

-6-

 

 

 

(xv) make any request or
submit any proposal to amend or waive the terms of this
Section 7
other than through non-public communications with Wrap that would
not be reasonably likely to trigger public disclosure obligations
for any Party;

 

(xvi) engage any private
investigations firm or other person to investigate any of
Wrap’s directors or officers;

 

(xvii) disclose in a
manner that could reasonably be expected to become public any
intent, purpose, plan or proposal with respect to any director or
Wrap’s management, policies, strategy, operations, financial
results or affairs, any of its securities or assets or this
Agreement that is inconsistent with the provisions of this
Agreement; or

 

(xviii) enter into any
discussions, negotiations, agreements or understandings with any
person with respect to any action the Norris Parties are prohibited
from taking pursuant to this Section 7, or finance, advise, assist,
knowingly encourage or seek to persuade any person to take any
action or make any statement with respect to any such action, or
otherwise take or cause any action or make any statement
inconsistent with any of the foregoing.

 

Notwithstanding
anything to the contrary contained in this Section 7, the Norris Parties shall not
be prohibited or restricted from: (A) communicating privately with
the Board or any officer or director of Wrap, in the manner set
forth for communicating with Wrap in the Company Policies,
regarding any matter, so long as such communications are not
intended to, and would not reasonably be expected to, require any
public disclosure of such communications by any of the Norris
Parties or their respective Affiliates, Wrap or its Affiliates or
any Third Party, subject in any case to any confidentiality
obligations to Wrap of any such director or officer and applicable
law, rules or regulations, (B) taking any action necessary to
comply with any law, rule or regulation or any action required by
any governmental or regulatory authority or stock exchange that
has, or may have, jurisdiction over any Norris Party, provided that a breach by the
Norris Parties of this Agreement is not the cause of the applicable
requirement, or (C) privately communicating to any of their
potential investors or investors factual information regarding
Wrap, provided such
communications are subject to reasonable confidentiality
obligations and are not otherwise reasonably expected to be
publicly disclosed.

 

(b) The provisions of
this Section 7 and other terms and
conditions set forth in this Agreement shall not limit in any
respect the actions of any director of Wrap in his or her capacity
as such, recognizing that such actions are subject to such
director’s fiduciary duties to Wrap and its stockholders and
the Company Policies. The Parties further agree and acknowledge
that neither the Norris Parties nor any of their Affiliates shall
seek to do indirectly through the New Directors (or any
Replacement) anything that would be prohibited if done by any of
the Norris Parties or their Affiliates. The provisions of this
Section 7 shall also not prevent the
Norris Parties from freely voting their shares of Common Stock
(except as otherwise provided in Section 4 hereto).

 

(c) During the
Standstill Period, each Norris Party shall refrain from taking any
actions which could have the effect of encouraging, assisting or
influencing other stockholders of Wrap or any other persons to
engage in actions which, if taken by any Norris Party, would
violate this Agreement.

 

(d) Notwithstanding
anything contained in this Agreement to the contrary, the
provisions of Sections 2, 4 and 5 of this Agreement shall
automatically terminate upon the consummation of a Change of
Control transaction agreed to by the Board if the acquiring or
counter-party to the Change of Control transaction has conditioned
the closing of the transaction on the termination of such
sections.

 

(e) During the
Standstill Period, each of the Norris Parties agrees not to, and to
cause its Representatives not to, comment publicly about any
director or Wrap’s management, policies, strategy,
operations, financial results or affairs or any transactions
involving Wrap or any of its subsidiaries, except as expressly
permitted by this Agreement.

 

(f) At any time the
Norris Parties cease to have the Norris Schedule 13D filed with the
SEC and during the Standstill Period, upon reasonable written
notice from Wrap pursuant to Section 18 herein, the Norris Parties
shall promptly provide Wrap with information regarding the amount
of the securities of Wrap (i) beneficially owned by each such
entity or individual, (ii) which the Norris Parties have (A) any
direct or indirect rights or options to acquire or (B) any economic
exposure through any derivative securities or contracts or
instruments in any way related to the price of such securities, or
(iii) with respect to which any Norris Party has hedged its
position by selling covered call options. This ownership
information provided to Wrap will be kept strictly confidential,
unless required to be disclosed pursuant to applicable laws and
regulations, any subpoena, legal process or other legal requirement
or in connection with any litigation or similar proceedings in
connection with this Agreement.

 

 

 

-7-

 

 

 

8. Representations
and Warranties of Wrap. Wrap represents
and warrants to the other Parties that (a) Wrap has the corporate
power and authority to execute this Agreement and to bind it
thereto, (b) this Agreement has been duly and validly authorized,
executed and delivered by Wrap, constitutes a valid and binding
obligation and agreement of Wrap, and is enforceable against Wrap
in accordance with its terms, except as enforcement thereof may be
limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or similar laws generally
affecting the rights and remedies of creditors and subject to
general equity principles, and (c) the execution, delivery and
performance of this Agreement by Wrap does not and will not violate
or conflict with (i) any law, rule, regulation, order, judgment or
decree applicable to it, or (ii) result in any breach or violation
of or constitute a default (or an event which with notice or lapse
of time or both could become a default) under or pursuant to, or
result in the loss of a material benefit under, or give any right
of termination, amendment, acceleration or cancellation of, any
organizational document, or any material agreement, contract,
commitment, understanding or arrangement to which Wrap is a party
or by which it is bound.

 

9. Representations
and Warranties of the Norris Parties. Each Norris Party
represents and warrants to the other Parties that (a) this
Agreement has been duly and validly authorized, executed and
delivered by such Norris Party, and constitutes a valid and binding
obligation and agreement of such Norris Party, enforceable against
such Norris Party in accordance with its terms, except as
enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or
similar laws generally affecting the rights and remedies of
creditors and subject to general equity principles, (b) the
signatory for such Norris Party has the power and authority to
execute this Agreement and any other documents or agreements
entered into in connection with this Agreement on behalf of itself
and the applicable Norris Party associated with that
signatory’s name, and to bind such Norris Party to the terms
hereof and thereof, (c) the execution, delivery and performance of
this Agreement by such Norris Party does not and will not violate
or conflict with (i) any law, rule, regulation, order, judgment or
decree applicable to it, or (ii) result in any breach or violation
of or constitute a default (or an event which with notice or lapse
of time or both could become a default) under or pursuant to, or
result in the loss of a material benefit under, or give any right
of termination, amendment, acceleration or cancellation of, any
organizational document, agreement, contract, commitment,
understanding or arrangement to which such member is a party or by
which it is bound and (d) the New Directors (or any Replacement)
will not be, and the Norris Parties will not consider the New
Directors (or any Replacement) to be, stockholder designees or
stockholder representatives of the Norris Parties.

 

10. SEC Filings.

 

(a) No later than two
(2) business days following the Effective Date, Wrap shall file
with the SEC a Current Report on Form 8-K reporting its entry into
this Agreement and appending this Agreement as an exhibit thereto
(the “Form
8-K”). The Form 8-K shall be consistent with the terms
of this Agreement. Wrap shall provide the Norris Parties with a
reasonable opportunity to review and comment on the Form 8-K prior
to the filing with the SEC and consider in good faith any comments
of the Norris Parties.

 

(b) No later than two
(2) business days following the Effective Date, the Norris Parties
shall file with the SEC an amendment to the Norris Schedule 13D, in
compliance with Section 13 of the Exchange Act reporting their
entry into this Agreement and appending this Agreement as an
exhibit thereto or incorporating this Agreement by reference to
Wrap’s Current Report on Form 8-K referred to in Section 10(a) hereof (the
“Schedule 13D
Amendment”). The Schedule 13D Amendment shall be
consistent with the terms of this Agreement. The Norris Parties
shall provide Wrap with a reasonable opportunity to review and
comment on the Schedule 13D Amendment prior to it being filed with
the SEC and consider in good faith any comments of
Wrap.

 

(c) Promptly following
the execution of this Agreement, Wrap shall issue a press release
(the “Press
Release”) in a form prepared by Wrap and approved by
the Norris Parties (such approval not to be unreasonably withheld).
Prior to the issuance of the Press Release, neither Wrap nor the
Norris Parties shall issue any press release or make any public
announcement regarding this Agreement or take any action that would
require public disclosure thereof without the prior written consent
of the other Parties, except to the extent required by applicable
law or the rules of any national securities exchange.

 

11. Term;
Termination. Unless otherwise
mutually agreed in writing by Wrap or the Norris Parties, the term
of this Agreement shall commence on the Effective Date and shall
continue until the date (the “Termination Date”) that is the
earliest of (a) the tenth day (the “Final Replacement Date”) following
the adjournment of the first applicable annual meeting of
Wrap’s stockholders, which follows the 2021 Annual Meeting,
at which the New Directors (or any Replacement) were not
successfully re-elected at such meeting and no subsequent
Replacements were appointed by the Board by the Final Replacement
Date, (b) the New Directors (or any Replacement) fail to be
re-nominated for election to the Board at any annual or special
meeting of Wrap’s stockholders (including any adjournment
postponement, rescheduling or continuation thereof) at which such
New Directors (or such Replacement) are up for election, and (c)
the consummation of an Extraordinary Transaction.

 

 

 

-8-

 

 

 

Notwithstanding
anything to the contrary herein, (i) the Norris Parties may earlier
terminate this Agreement if Wrap commits a material breach of its
obligations under this Agreement that (if capable of being cured)
is not cured within fifteen (15) days after receipt by Wrap from a
Norris Party specifying the material breach, or, if impossible to
cure within fifteen (15) days, that Wrap has not taken any
substantive action to cure within such fifteen (15)-day period, and
(ii) Wrap may earlier terminate this Agreement if any of the Norris
Parties commits a material breach of this Agreement that (if
capable of being cured) is not cured within fifteen (15) days after
receipt by such Norris Party from Wrap specifying the material
breach, or, if impossible to cure within fifteen (15) days, that
such Norris Party has not taken any substantive action to cure
within such fifteen (15)-day period. Termination of this Agreement
shall not relieve any Party from its responsibilities in respect of
any breach of this Agreement prior to such termination. The Parties
agree that if the Board does not comply with the provisions of
Section 2(a)(ii) hereof by the Appointment Date and such
non-compliance is not directly the result of a breach by the Norris
Parties of their obligations under this Agreement, then (x) such
non-compliance shall constitute a material breach of Wrap’s
obligations hereunder and that the cure period set forth in clause
(i) above shall not apply to such material breach; and (y) if the
Norris Parties exercise their termination right upon such
non-compliance, Wrap agrees that (A) so long as the Norris Group
provides a notice in the same form as the Nomination Notice (the
“Subsequent Nomination Notice”) within 10 days after
such termination, such notice will be deemed timely with respect to
nominations and proposals for consideration at the 2021 Annual
Meeting and (y) the Company shall not include in the Proxy
Statement any statement that would permit a proxy to confer
discretionary authority with respect to the matters set forth in
such Subsequent Nomination Notice (or if the Proxy Statement has
been issued at the date of such Subsequent Nomination Notice, Wrap
shall amend the Proxy Statement to the extent necessary to remove
any such statement).

 

12. Expenses.
Each Party shall be responsible for its own fees and expenses in
connection with the negotiation and execution of this Agreement and
the transactions contemplated hereby; provided, however, that Wrap shall
promptly reimburse Norris for the reasonable, documented
out-of-pocket fees and expenses incurred by the Norris Parties in
connection with the negotiation and execution of this Agreement and
the transactions contemplated hereby in an amount not to exceed in
the aggregate $150,000.

 

13. No
Other Discussions or Arrangements. The Norris
Parties represent and warrant that, as of the date of this
Agreement, except as specifically disclosed on the Norris Schedule
13D, or as disclosed to Wrap in writing prior to the Effective
Date, (a) the Norris Parties do not own, of record or beneficially,
any Voting Securities or any securities convertible into, or
exchangeable or exercisable for, any Voting Securities and (b) the
Norris Parties have not entered into, directly or indirectly, any
agreements or understandings with any person (other than their own
Representatives) with respect to any potential transaction
involving Wrap or the voting or disposition of any securities of
Wrap.

 

14. Governing Law;
Jurisdiction. This Agreement
shall be governed by and construed in accordance with the internal
laws of the State of Delaware without giving effect to any choice
or conflict of law provision or rule that would cause the
application of laws of any jurisdiction other than those of the
State of Delaware. Each Party agrees that it shall bring any suit,
action or other proceeding in respect of any claim arising out of
or related to this Agreement (each, an “Action”) exclusively in (a) the
Delaware Court of Chancery in and for New Castle County, (b) in the
event (but only in the event) that such court does not have subject
matter jurisdiction over such Action, the United States District
Court for the District of Delaware or (c) in the event (but only in
the event) such courts identified in clauses (a) and (b) do not
have subject matter jurisdiction over such Action, any other
Delaware state court (collectively, the “Chosen Courts”), and, solely in
connection with an Action, (i) irrevocably submits to the exclusive
jurisdiction of the Chosen Courts, (ii) irrevocably submits to the
exclusive venue of any such Action in the Chosen Courts and waives
any objection to laying venue in any such Action in the Chosen
Courts, (iii) waives any objection that the Chosen Courts are an
inconvenient forum or do not have jurisdiction over any Party
hereto and (iv) agrees that service of process upon such Party in
any such Action shall be effective if notice is given in accordance
with Section
18 of this
Agreement. Each Party agrees that a final judgment in any Action
brought in the Chosen Courts shall be conclusive and binding upon
each of the Parties and may be enforced in any other court, the
jurisdiction of which each of the Parties is or may be subject, by
suit upon such judgment. Notwithstanding the foregoing, nothing in
this Section
14 shall limit the
appeal rights in any Action for any Party.

 

 

 

-9-

 

 

 

15. Waiver of Jury
Trial. EACH PARTY HERETO
ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER
THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND
UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS
AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF
ANY OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING
WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS
CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES
THIS WAIVER VOLUNTARILY AND (D) SUCH PARTY HAS BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 15.

 

16. Specific
Performance. Each of the
Parties acknowledges and agrees that irreparable injury to the
other Party would occur in the event any of the provisions of this
Agreement are not performed in accordance with their specific terms
or are otherwise breached and that such injury would not be
adequately compensable by the remedies available at law (including
the payment of money damages). It is accordingly agreed that each
of the Parties (the “Moving
Party”) shall be entitled to specific enforcement of,
and injunctive or other equitable relief as a remedy for any such
breach or to prevent any violation or threatened violation of, the
terms hereof, and the other Party will not take action, directly or
indirectly, in opposition to the Moving Party seeking such relief
on the grounds that any other remedy or relief is available at law
or in equity. The Parties further agree to waive any requirement
for the security or posting of any bond in connection with any such
relief. The remedies available pursuant to this Section 16 shall not be deemed to be
the exclusive remedies for a breach of this Agreement but shall be
in addition to all other remedies available at law or
equity.

 

17. Certain
Definitions. As used in this
Agreement:

 

(a) “Affiliate” shall mean any
“Affiliate” as
defined in Rule 12b-2 promulgated by the SEC under the Exchange
Act, including, for the avoidance of doubt, persons who become
Affiliates subsequent to the Effective Date;

 

(b) “Associate” shall mean any
“Associate” as
defined in Rule 12b-2 promulgated by the SEC under the Exchange
Act, including, for the avoidance of doubt, persons who become
Associates subsequent to the Effective Date;

 

(c) “beneficial owner”,
“beneficial
ownership” and “beneficially own” shall have the
same meanings as set forth in Rule 13d-3 promulgated by the SEC
under the Exchange Act;

 

(d) “business day” shall mean any day
other than a Saturday, Sunday or day on which the commercial banks
in the State of New York are authorized or obligated to be closed
by applicable law;

 

(e) a
“Change of
Control” transaction shall be deemed to have taken
place if (i) any person is or becomes a beneficial owner, directly
or indirectly, of securities of Wrap representing more than fifty
percent (50%) of the equity interests and voting power of
Wrap’s then-outstanding equity securities or (ii) Wrap enters
into a stock-for-stock transaction whereby immediately after the
consummation of the transaction Wrap’s stockholders retain
less than fifty percent (50%) of the equity interests and voting
power of the surviving entity’s then-outstanding equity
securities;

 

(f) “Extraordinary Transaction” shall
mean any equity tender offer, equity exchange offer, merger,
acquisition, business combination, or other transaction with a
Third Party that, in each case, would result in a Change of
Control, liquidation, dissolution or other extraordinary
transaction involving a majority of its equity securities or a
majority of its assets, and, for the avoidance of doubt, including
any such transaction with a Third Party that is submitted for a
vote of Wrap’s stockholders;

 

(g) “other Party” shall mean, with
respect to Wrap, any of the Norris Parties, and with respect to the
Norris Parties, Wrap;

 

 

 

-10-

 

 

 

(h) “person” or “persons” shall mean any
individual, corporation (including not-for-profit), general or
limited partnership, limited liability company, joint venture,
estate, trust, association, organization or other entity of any
kind, structure or nature;

 

(i)  “Representative”
shall mean a person’s Affiliates and Associates and its and
their respective directors, officers, employees, partners, members,
managers, family members, consultants, legal or other advisors,
agents and other representatives; provided, that when used with
respect to Wrap, “Representatives” shall not include
any non-executive employees; and

 

(j) “Voting Securities” means the
Common Stock and any other securities of Wrap entitled to vote in
the election of directors.

 

18. Notices. All notices,
requests, consents, claims, demands, waivers, and other
communications hereunder shall be in writing and shall be deemed to
have been given: (a) when delivered by hand (with written
confirmation of receipt), (b) when received by the addressee if
sent by a nationally recognized overnight courier (receipt
requested), (c) on the date sent by facsimile or email (with
confirmation of transmission) if sent during normal business hours,
and on the next business day if sent after normal business hours,
or (d) on the third day after the date mailed, by certified or
registered mail, return receipt requested, postage prepaid. Such
communications must be sent to the respective Parties at the
addresses set forth in this Section 18 (or to such other address
that may be designated by a Party from time to time in accordance
with this Section 18).

 

If to
Wrap, to its address at:

 

Wrap
Technologies, Inc.

1817 W
4th
Street

Tempe,
AZ 85281

Attention: Wayne
Walker

Email:
WWalker@Walkernell.com

 

With
copies (which shall not constitute notice) to:

 

Vinson
& Elkins L.L.P.

1114
Avenue of the Americas, 32nd Floor

New
York, NY 10036

Attention: Lawrence
S. Elbaum

 C. Patrick
Gadson

Email:
lelbaum@velaw.com

pgadson@velaw.com

 

Disclosure Law
Group

655
West Broadway, Suite 870

San
Diego, CA 92101

Attention: Daniel
W. Rumsey

Email:
drumsey@disclosurelawgroup.com

 

 

If to a
Norris Party, to the address at:

 

15891
Blue Crystal Trail

Poway,
CA 92064

Attention: Elwood
G. Norris

Email:
woodynorris@cox.net

 

With a
copy (which shall not constitute notice) to:

 

Sheppard Mullin
Richter & Hampton LLP

12275
El Camino Real, Suite 200

San
Diego, CA 92130

Attention: John D.
Tishler

Email:
JTishler@sheppardmullin.com

 

 

-11-

 

 

 

19. Entire
Agreement. This Agreement
constitutes the sole and entire agreement of the Parties with
respect to the subject matter contained herein, and supersedes all
prior and contemporaneous understandings, agreements,
representations, and warranties, both written and oral, with
respect to such subject matter. This Agreement may only be amended,
modified, or supplemented by an agreement in writing signed by each
Party.

 

20. Severability.
If any term or provision of this Agreement is invalid, illegal, or
unenforceable in any jurisdiction, such invalidity, illegality, or
unenforceability shall not affect any other term or provision of
this Agreement or invalidate or render unenforceable such term or
provision in any other jurisdiction.

 

21. Counterparts.
This Agreement may be executed in counterparts, each of which shall
be deemed an original, but all of which together shall be deemed to
be one and the same agreement. A signed copy of this Agreement
delivered by facsimile, email, or other means of electronic
transmission shall be deemed to have the same legal effect as
delivery of an original signed copy of this Agreement.

 

22. Assignment. No Party may
assign any of its rights or delegate any of its obligations
hereunder without the prior written consent of the other Parties;
provided, that each
Party may assign any of its rights and delegate any of its
obligations hereunder to any person or entity that acquires
substantially all of that Party’s assets, whether by stock
sale, merger, asset sale or otherwise. Any purported assignment or
delegation in violation of this Section 22 shall be null and void. No
assignment or delegation shall relieve the assigning or delegating
Party of any of its obligations hereunder. This Agreement is for
the sole benefit of the Parties and their respective successors and
permitted assigns and nothing herein, express or implied, is
intended to or shall confer upon any other person or entity any
legal or equitable right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.

 

23. Waivers.
No waiver by any Party of any of the provisions hereof shall be
effective unless explicitly set forth in writing and signed by the
Party so waiving. No waiver by any Party shall operate or be
construed as a waiver in respect of any failure, breach, or default
not expressly identified by such written waiver, whether of a
similar or different character, and whether occurring before or
after that waiver. No failure to exercise, or delay in exercising,
any right, remedy, power, or privilege arising from this Agreement
shall operate or be construed as a waiver thereof; nor shall any
single or partial exercise of any right, remedy, power, or
privilege hereunder preclude any other or further exercise thereof
or the exercise of any other right, remedy, power, or
privilege.

 

 

 

[Remainder
of Page Intentionally Left Blank]

 

 

-12-

 

 

IN WITNESS WHEREOF, the Parties have
executed this Agreement to be effective as of the Effective
Date.

 

	
 

	
 

WRAP:

 

WRAP
TECHNOLOGIES, INC.

 

By:
/s/ Scot
Cohen

Name:
Scot Cohen

Title: Executive
Chairman

 

 

 

Signature Page to

Cooperation Agreement

 

 

-13-

 

 

 

	
 

	
 

NORRIS
PARTIES:

 

ELWOOD
G. NORRIS

 

By:
/s/ Elwood G.
Norris                                                                

 

 

STEPHANIE
A. NORRIS

 

By:
/s/ Stephanie A.
Norris                                                      

 

 

NORRIS
FAMILY 1997 TRUST

 

By:
/s/ Elwood G.
Norris                                                                

Name:
Elwood G. Norris

Title:
Trustee

 

 

 

Signature Page to

Cooperation Agreement

 

 

-14-Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of March 8, 2021, between PainReform Ltd., a company formed under the
laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each,
including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

 

WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser,
and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described
in this Agreement.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1 Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:

 

“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.5.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification,
commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”,
“non-essential employee”  or any other similar orders or restrictions or the closure of any physical branch locations
at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers)
of commercial banks in The City of New York are generally are open for use by customers on such day.

 

“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii)
the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived.

 

    1

    

    

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Company
Counsel” means McDermott Will & Emery LLP, with offices located at 340 Madison Avenue, New York, NY.

 

“Disclosure
Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

 

“Disclosure
Time” means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time)
on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof.

 

“Effective
Date” means the earliest of the date that (a) the initial Registration Statement has been declared effective by the Commission,
(b) all of the Shares and Warrant Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale
restrictions, (c) following the one year anniversary of the Closing Date provided that a holder of Shares or Warrant Shares is
not an Affiliate of the Company, or (d) all of the Shares and Warrant Shares may be sold pursuant to an exemption from registration
under Section 4(a)(1) of the Securities Act without volume or manner-of-sale restrictions and Company Counsel has delivered to
such holders a standing written unqualified opinion that resales may then be made by such holders of the Shares and Warrant Shares
pursuant to such exemption which opinion shall be in form and substance reasonably acceptable to such holders.

 

“EGS”
means Ellenoff Grossman & Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.

 

“Escrow
Agent” means EGS.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(s).

 

    2

    

    

 

“Exempt
Issuance” means the issuance of (a) Ordinary Shares or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or
a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
(b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent
in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent
and/or other securities exercisable or exchangeable for or convertible into Ordinary Shares issued and outstanding on the date
of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with share splits or combinations) or to extend the term of such securities and (c) securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are
issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided
that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the
Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“FDA”
shall have the meaning ascribed to such term in Section 3.1(ll).

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“IIA”
shall have the meaning ascribed to such term in Section 3.1(l).

 

“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(bb).

 

“Institutions”
shall have the meaning ascribed to such term in Section 3.1(p).

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).

 

“Israeli
Counsel” means Doron, Tikotzky, Kantor, Gutman & Amit Gross, with offices located at B.S.R. 4 Tower, 33 Floor, Metsada
Street, Bnei Brak 5126112 Israel.

 

“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.1(c).

 

“Liens”
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Lock-Up
Agreement” means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers,
in the form agreed to between the Company and the Purchasers.

 

    3

    

    

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).

 

“Ordinary
Shares” means the ordinary shares of the Company, nominal value NIS 0.03 per share, and any other class of securities
into which such securities may hereafter be reclassified or changed.

 

“Ordinary
Share Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Ordinary Shares, including, without limitation, any debt, preferred shares, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive, Ordinary Shares.

 

“Per
Share Purchase Price” equals $4.60, subject to adjustment for reverse and forward share splits, share dividends, share
combinations and other similar transactions of the Ordinary Shares that occur after the date of this Agreement.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Pharmaceutical
Product” shall have the meaning ascribed to such term in Section 3.1(ll).

 

“Placement
Agent” means Maxim Group LLC.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Public
Information Failure” shall have the meaning ascribed to such term in Section 4.2(b).

 

“Public
Information Failure Payments” shall have the meaning ascribed to such term in Section 4.2(b).

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.8.

 

“Registration
Rights Agreement” means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the
Purchasers, in the form agreed to by the Company and Purchasers.

 

“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement and
covering the resale by the Purchasers of the Shares and the Warrant Shares.

 

    4

    

    

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities”
means the Shares, the Warrants and the Warrant Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means the Ordinary Shares issued or issuable to each Purchaser pursuant to this Agreement.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing Ordinary Shares). 

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,”
in United States dollars and in immediately available funds.

 

“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a) and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Ordinary Shares are listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement, the Warrants, the Registration Rights Agreement, the Lock-Up Agreement, all exhibits
and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated
hereunder.

 

    5

    

    

 

“Transfer
Agent” means American Stock Transfer & Trust Company, the transfer agent of the Company, with a mailing address of
6201 15th Avenue, Brooklyn, New York 11219, and any successor transfer agent of the Company.

 

“Variable
Rate Transaction” shall have the meaning ascribed to such term in Section 4.12(b).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares then listed
or quoted on a Trading Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding
date) on the Trading Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Ordinary Share are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are
then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Ordinary Shares so reported, or (d) in all other cases, the fair market value of an
Ordinary Share as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of
the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“Warrants”
means, collectively, the Ordinary Share purchase warrants delivered to the Purchasers at the Closing in accordance with Section
2.2(a) hereof, which Warrants shall be exercisable immediately after the Closing Date and have a term of exercise equal to five
and one-half (5.5) years from the initial exercise date, in the form agreed to by the Company and Purchasers.

 

“Warrant
Shares” means the Ordinary Shares issuable upon exercise of the Warrants.

 

ARTICLE II.

PURCHASE AND SALE

 

2.1 Closing.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $6,000,000 of Shares and Warrants. Each Purchaser shall deliver to the Escrow Agent, via
wire transfer or a certified check, immediately available funds equal to such Purchaser’s Subscription Amount as set forth
on the signature page hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective Shares
and a Warrant, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth
in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3,
the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree.

 

    6

    

    

 

2.2 Deliveries.

 

(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

(i) this
Agreement duly executed by the Company;

 

(ii) a
legal opinion of Company Counsel, in form and substance reasonably acceptable to the Purchasers and the Placement Agent;

 

(iii) a
legal opinion of Israeli Counsel, in form and substance reasonably acceptable to the Purchasers and the Placement Agent;

 

(iv) a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis a certificate
evidencing a number of Shares equal to such Purchaser’s Subscription Amount divided by the Per Share Purchase Price, registered
in the name of such Purchaser, or, at the election of such Purchaser, evidence of the issuance of such Purchaser’s Shares
hereunder as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser, which evidence shall
be reasonably satisfactory to such Purchaser;

 

(v) a
Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares equal to 50% of such Purchaser’s
Shares, with an exercise price equal to $4.60, subject to adjustment therein;

 

(vi) the
Company shall have provided each Purchaser with the Company’s wire instructions, on Company letterhead and executed by the
Chief Executive Officer or Chief Financial Officer;

 

(vii) the
Lock-Up Agreements; and

 

(viii) the
Registration Rights Agreement duly executed by the Company.

 

(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company or the Escrow Agent, as applicable,
the following:

 

(i) this
Agreement duly executed by such Purchaser;

 

(ii) to
the Escrow Agent, such Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the Escrow
Agent; and

 

(iii) the
Registration Rights Agreement duly executed by such Purchaser.

 

    7

    

    

 

2.3 Closing
Conditions.

 

(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);

 

(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and

 

(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

 

(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:

 

(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);

 

(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

 

(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(iv) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

 

(v) from
the date hereof to the Closing Date, trading in the Ordinary Shares shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.

 

    8

    

    

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1 Representations
and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:

 

(a) Subsidiaries.
All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

 

(b) Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective memorandum and articles of association,
certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries
is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in
which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure
to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material
adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results
of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as
a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and
no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification. The Company’s articles of association and other constitutive or organizational
documents of the Company comply with the requirements of applicable Israeli law and are in full force and effect.

 

(c) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s shareholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

    9

    

    

 

(d) No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) or, except as set forth on Schedule 3.1(d), anti-dilution
or similar adjustments of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, including but not limited to (x) any instrument of approval granted to any of them by the
Israel Innovation Authority of the Israeli Ministry of Economy and Industry, or (y) any instrument of approval granted to any of
them by the Investment Center of the Israeli Ministry of Economy and Industry, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(e) Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission pursuant to the Registration
Rights Agreement, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities
and the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv) the filing
of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively,
the “Required Approvals”). Assuming the Placement Agent has not and will not offer or sell Shares in Israel
other than to investors listed in the Addendum to the Israeli Securities Law (1968-5728) (the “Addendum”) who submit
to the Placement Agent the requisite written confirmations under the Addendum, the Company is not required to publish a prospectus
in the State of Israel under the laws of the State of Israel with respect to the offer and sale of the Shares.

 

(f) Issuance
of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company.
The Warrant Shares are duly authorized and, when issued in accordance with the terms of the Warrants, will be validly issued, fully
paid and non-assessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized
share capital the maximum number of Ordinary Shares issuable pursuant to this Agreement and the Warrants. The Securities are not
and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company.

 

    10

    

    

 

(g) Capitalization.
The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g), which Schedule 3.1(g)
shall also include the number of Ordinary Shares Stock owned beneficially, and of record, by Affiliates of the Company as of the
date hereof. The Company has not issued any share capital since its most recently filed periodic report under the Exchange Act,
other than pursuant to the exercise of employee share options under the Company’s share option plans, the issuance of Ordinary
Shares to employees pursuant to the Company’s employee share purchase plans and pursuant to the conversion and/or exercise
of Ordinary Share Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except
as set forth in Schedule 3.1(g), no Person has any right of first refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale
of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire, any Ordinary Shares or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional Ordinary Shares
or Ordinary Share Equivalents or capital stock of any Subsidiary. Except as set forth on Schedule 3.1(g), there are no outstanding
securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or
reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. The issuance and sale
of the Securities will not obligate the Company or any Subsidiary to issue Ordinary Shares or other securities to any Person (other
than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any share appreciation
rights or “phantom share” plans or agreements or any similar plan or agreement. All of the outstanding share capital
of the Company is duly authorized, validly issued, fully paid and nonassessable, has been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights
to subscribe for or purchase securities. The authorized shares of the Company conform in all material respects to all statements
relating thereto contained in the SEC Reports (as defined below). The offers and sales of the Company’s securities were at
all relevant times either registered under the Securities Act and the applicable state securities or Blue Sky laws or, based in
part on the representations and warranties of the purchasers, exempt from such registration requirements. No further approval or
authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except
as set forth in Schedule 3.1(g), there are no shareholders agreements, voting agreements or other similar agreements with respect
to the Company’s share capital to which the Company is a party or, to the knowledge of the Company, between or among any
of the Company’s shareholders.

 

(h) SEC
Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of
filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC
Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
adjustments.

 

    11

    

    

 

(i) Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on Schedule 3.1(i), (i) there has been no event, occurrence or development that
has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its share capital and (v) the Company has not issued any equity securities to
any officer, director or Affiliate except pursuant to existing Company option plans. The Company does not have pending before the
Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this
Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected
to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations,
assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time
this representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that
this representation is made. Except as set forth in Schedule 3.1(i), unless otherwise disclosed in the SEC Reports, the
Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or
(ii) declared or paid any dividend or made any other distribution on or in respect to its share capital.

 

(j) Litigation.
Except as set forth on Schedule 3.1(j), there has not been, and to the knowledge of the Company there is not pending or
contemplated, any action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been,
and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company
or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act. No proceedings have been instituted in the State of Israel for the dissolution of the Company. The Company and the Subsidiaries
are not currently designated as a “breaching company” (within the meaning of the Israeli Companies Law 5759-1999, and
the regulations thereunder by the Registrar of Companies of the State of Israel), nor has a proceeding been instituted by the Registrar
of Companies in Israel for the dissolution of the Company or the Subsidiaries.

 

    12

    

    

 

(k) Labor
Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters that would reasonably expect to have a Material
Adverse Effect. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws
and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours and employment
laws and collective bargaining agreements and extension orders applicable to their employees in the State of Israel, except where
the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.

 

(l) Compliance.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), including but not limited to (x) any instrument of approval granted
to any of them by the Israel Innovation Authority of the Israeli Ministry of Economy and Industry (formerly the Office of the Chief
Scientist) (the “IIA”), or (y) any instrument of approval granted to any of them by the Investment Center of
the Israeli Ministry of Economy and Industry, (ii) is in violation of any judgment, decree or order of any court, arbitrator or
other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign (including Israeli), federal, state and local laws, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.

 

(m) Environmental
Laws. To the extent applicable to the Company and its Subsidiaries, the Company and its Subsidiaries (i) are in compliance
with all applicable federal, state, local and foreign (including Israeli) laws relating to pollution or protection of human health
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating
to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances
or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans
or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)
and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect.

 

    13

    

    

 

(n) Regulatory
Permits. The Company and the Subsidiaries possess all certificates, authorizations, approvals, orders, licenses and permits
issued by the appropriate federal, state, local or foreign (including Israeli) regulatory authorities necessary to conduct their
respective businesses as described in the SEC Reports (each, a “Material Permit”),
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect,
and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of
any Material Permit. The disclosures in the SEC Reports concerning the effects of federal, state, local and all foreign regulation
on the Company’s business as currently contemplated are correct in all material respects.

 

(o) Title
to Assets. The Company and the Subsidiaries have good and marketable title in fee simple or have valid and marketable rights
to lease or otherwise use, all real property and personal property used by them that is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and the Subsidiaries are in compliance.

 

(p) Intellectual
Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)
years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Company’s
business or planned business as described in the SEC Reports violates or infringes upon the rights of any Person, except as could
not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights.
The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all
of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. The Company is not and has not collected or received any grant, funding or related payment from
the IIA, or any public university or academic facility, medical center or related research institutions (the “Institutions”),
nor have any of the Institutions, directly or indirectly, taken any part in the development or production of the Company’s
intellectual property or products (including intellectual property or products currently under development).

 

    14

    

    

 

(q) Insurance.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business without a significant increase in cost.

 

(r) Transactions
with Affiliates and Employees. Except as set forth on Schedule 3.1(r), of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from, any officer,
director or such employee or, to the knowledge of the company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, shareholder, member or partner, in each case in excess of $120,000
other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf
of the Company and (iii) other employee benefits, including share option agreements under any share option plan of the Company.

 

(s) Sarbanes-Oxley;
Internal Accounting Controls. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth in the SEC
Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and
the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial
reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially adversely affected,
or is reasonably likely to materially adversely affect, the internal control over financial reporting of the Company and its Subsidiaries.

 

    15

    

    

 

(t) Certain
Fees. Other than fees payable to the Placement Agent, no brokerage or finder’s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in
this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(u) Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.

 

(v) Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject
to registration under the Investment Company Act of 1940, as amended.

 

(w) Registration
Rights. Except as set forth on Schedule 3.1(w), other than each of the Purchasers, no Person has any right to cause the Company
or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

 

(x) Listing
and Maintenance Requirements. The Ordinary Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Ordinary Shares under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Ordinary Shares are or have been listed or quoted to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Ordinary Shares are
currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and
the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation)
in connection with such electronic transfer.

 

    16

    

    

 

(y) Application
of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

 

(z) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information. The Company understands
and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company.
All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their
respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases,
together with the Reports of Foreign Private Issuer on Form 6-K, disseminated by the Company during the twelve months preceding
the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section
3.2 hereof.

 

    17

    

    

 

(aa) No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require
the registration of any such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.

 

(bb) Solvency.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds
the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 3.1(bb)
sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which
the Company or any Subsidiary has commitments. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.
“Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than
trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required
to be capitalized in accordance with GAAP.

 

(cc) Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all applicable income and franchise tax returns,
reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments
and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has
set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods
to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.
The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement
are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such
consolidated financial statements. The term “taxes” mean all federal, state, local, foreign, and other net income,
gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes,
fees, assessments, or charges of any kind whatsoever, together with any interest and any penalties, additions to tax, or additional
amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements, and other documents
required to be filed in respect to taxes.

 

    18

    

    

 

(dd) Israeli
Taxes. Assuming that the Purchasers are not otherwise subject to taxation in the State of Israel due to Israeli tax residence
or the existence of a permanent establishment in Israel, the issuance, delivery and sale of the Shares by the Company and any subsequent
resale by such Purchaser will not be subject to any tax (including interest and penalties) imposed on any Purchaser by the State
of Israel or any political subdivision thereof, whether imposed directly or through withholding. The Purchasers are not required
to withhold for Israeli tax purposes any portion of the consideration for the Shares being issued and sold by the Company.

 

(ee) No
General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers
and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

 

(ff) Foreign
Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision
of FCPA. The Company has taken commercially reasonable steps to ensure that its accounting controls and procedures are designed
to cause the Company to comply in all material respects with the FCPA and Title 5 of the Israeli Penalty Law (Bribery Transactions).

 

    19

    

    

 

(gg) Accountants.
The Company’s accounting firm is Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network. To the knowledge
and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and
(ii) shall express its opinion with respect to the financial statements to be included in the Company’s Annual Report for
the fiscal year ended December 31, 2020.

 

(hh)
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company
further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(ii) Acknowledgment
Regarding Purchaser’s Trading Activity. Anything in
this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.14 hereof), it is understood
and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser
agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities
based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or
other transactions by any Purchaser, specifically including, without limitation, Short Sales or “derivative” transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company’s
publicly-traded securities, (iii) any Purchaser, and counter-parties in “derivative” transactions to which any such
Purchaser is a party, directly or indirectly, presently may have a “short” position in the Ordinary Shares and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative”
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that
the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if
any) could reduce the value of the existing shareholders’ equity interests in the Company at and after the time that the hedging
activities are being conducted.  The Company acknowledges that such aforementioned hedging activities do not constitute a
breach of any of the Transaction Documents.

 

    20

    

    

 

(jj) Regulation
M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement
agent in connection with the placement of the Securities.

 

(kk) FDA.
The clinical and preclinical studies conducted by or on behalf of the Company and the Subsidiaries if still ongoing, are being
conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions in which they are being
conducted. The Company has no knowledge of, or reason to believe that, any clinical study the aggregate results of which are inconsistent
with or otherwise call into question the results of any clinical study conducted by or on behalf of the Company and the Subsidiaries.
The Company has not received any written notices or statements from the U.S. Food and Drug Administration (“FDA”),
the European Medicines Agency or any other governmental agency or authority requiring, requesting or suggesting termination, suspension
or material modification for or of any clinical or preclinical studies or the results of. The Company has not received any written
notices or statements from any governmental agency, and otherwise has no knowledge of, or reason to believe that any license, approval,
permit or authorization to conduct any clinical trial of any potential product of the Company has been, will be or may be suspended,
revoked, modified or limited. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any
lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company
or any of the Subsidiaries, and none of the Company or any of the Subsidiaries has received any notice, warning letter or other
communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling
and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or
withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)
imposes a clinical hold on any clinical investigation by the Company or any of the Subsidiaries, (iv) enjoins production at any
facility of the Company or any of the Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction
with the Company or any of the Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company
or any of the Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties,
business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA.  The Company has not been informed by the FDA that the FDA will prohibit the marketing,
sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has
the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed
by the Company. For purposes of this Section, “Pharmaceutical Product” means each product subject to the jurisdiction
of the FDA under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of the Subsidiaries.

 

    21

    

    

 

(ll) Foreign
Private Issuer. The Company is and, following the consummation of the transactions contemplated hereby will be, a “foreign
private issuer” within the meaning of Rule 405 under the Securities Act.

 

(mm) Share
Option Plans. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly
grant, share options prior to, or otherwise knowingly coordinate the grant of share options with, the release or other public announcement
of material information regarding the Company or its Subsidiaries or their financial results or prospects.

 

(nn) Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(oo) U.S.
Real Property Holding Corporation; PFIC. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended (including the applicable rules and regulations promulgated
thereunder, the “Code”). Based on the Company’s current income and assets and projections as to the value
of its assets and the market value of its Ordinary Shares, including the current and anticipated valuation of its assets, the Company
does not believe it was a Passive Foreign Investment Company (“PFIC”) within the meaning of Section 1297 of
the Code, for its most recent taxable year, and does not expect to become a PFIC for its current taxable year or in the foreseeable
future.

 

(pp) Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%)
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

(qq) Money
Laundering. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with
applicable financial record keeping and reporting requirements and money laundering statutes of the United States, Israel and,
to the Company’s knowledge, all other jurisdictions to which the Company and the Subsidiaries are subject, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable
governmental agency, including the Currency and Foreign Transactions Reporting Act of 1970, as amended, and the Israeli Prohibition
on Money Laundering Law, 2000 (collectively, the “Money Laundering Laws”) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of the Subsidiaries
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

 

    22

    

    

 

(rr) No
Disqualification Events.  With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under
the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”
and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.

 

(ss) Other
Covered Persons. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale
of any Securities.

 

(tt) Notice
of Disqualification Events. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of
time, become a Disqualification Event relating to any Issuer Covered Person.

 

(uu) Officers’
Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to the Placement Agent, the
Purchasers or EGS shall be deemed a representation and warranty by the Company to the Purchasers as to the matters covered thereby.

 

(vv) No
Immunity. To the extent that the Company has or hereafter may acquire any immunity (sovereign or otherwise) from jurisdiction
of any court of (i) the State of Israel, or any political subdivision thereof, (ii) the United States or the State of New York,
(iii) any jurisdiction in which it owns or leases property or assets or from any legal process (whether through service of notice,
attachment prior to judgment, attachment in aid of execution, execution, set-off or otherwise) with respect to themselves or their
respective property and assets or this Agreement and the Transaction Documents, the Company hereby irrevocably waives such immunity
in respect of its obligations under this Agreement and the Transaction Documents to the fullest extent permitted by applicable
law..

 

    23

    

    

 

(ww) Validity
of Choice of Law. The choice of the laws of the State of New York as the governing law of this Agreement is a valid choice
of law under the laws of Israel and will be honored by courts in Israel. The Company has the power to submit, and pursuant to this
Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each New York State and
United States Federal court sitting in The City of New York (each, a “New York Court”) and has validly and irrevocably
waived any objection to the laying of venue of any suit, action or proceeding brought in any such court.

 

(xx) Enforceability
of Judgment.  Any final judgment for a fixed or determined sum of money rendered by any U.S. federal or New York state
court located in the State of New York having jurisdiction under its own laws in respect of any suit, action or proceeding against
the Company based upon this Agreement would be declared enforceable against the Company by the courts of the State of Israel, without
reconsideration or reexamination of the merits, subject to the conditions, qualifications and restrictions described under the
caption “Enforceability of Civil Liabilities” in the SEC Reports.

 

3.2 Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):

 

(a) Organization;
Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

(b) Own
Account. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to
distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration
Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.

 

    24

    

    

 

(c) Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act.

 

(d) Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e) General
Solicitation. Such Purchaser is not, to such Purchaser’s knowledge, purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast
over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or
general advertisement.

 

(f) Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has
deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering
of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its
financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. 
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. 
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities
and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it.  In connection with the issuance of the Securities to such Purchaser, neither the Placement
Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.

 

    25

    

    

 

(g) Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser’s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales
or similar transactions in the future.

 

The Company acknowledges
and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser’s right
to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1 Transfer
Restrictions.

 

(a) The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in
connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company
an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the
terms of this Agreement and the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this
Agreement and the Registration Rights Agreement.

 

    26

    

    

 

(b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:

 

THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS
SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED
BY SUCH SECURITIES.

 

The Company
acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser
may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to
approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection
therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser’s expense, the Company will
execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection
with a pledge or transfer of the Securities, including, if the Securities are subject to registration pursuant to the Registration
Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act
or other applicable provision of the Securities Act to appropriately amend the list of Selling Shareholders (as defined in the
Registration Rights Agreement) thereunder.

 

    27

    

    

 

(c) Certificates
evidencing the Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof),
(i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under
the Securities Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise of
the Warrants), (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants),
or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the
Transfer Agent or the Purchaser promptly after the Effective Date if required by the Transfer Agent to effect the removal of the
legend hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant is exercised at a time when
there is an effective registration statement to cover the resale of the Warrant Shares, or if such Shares or Warrant Shares may
be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144 (assuming
cashless exercise of the Warrants), or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for the
Company to be in compliance with the current public information required under Rule 144 as to such Shares or Warrant Shares or
if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company
agrees that following the Effective Date or at such time as such legend is no longer required under this Section 4.1(c), it will,
no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
(as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares
or Warrant Shares, as the case may be, issued with a restrictive legend (such date, the “Legend Removal Date”),
deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and
other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the
restrictions on transfer set forth in this Section 4. Certificates for Securities subject to legend removal hereunder shall be
transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository
Trust Company System as directed by such Purchaser. As used herein, “Standard Settlement Period” means the standard
settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Ordinary
Shares as in effect on the date of delivery of a certificate representing Shares or Warrants Shares, as the case may be, issued
with a restrictive legend.

 

(d) In
addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the VWAP of the Ordinary Shares on the date
such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c),
$10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each
Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to
(a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities
so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal
Date such Purchaser purchases (in an open market transaction or otherwise) Ordinary Shares to deliver in satisfaction of a sale
by such Purchaser of all or any portion of the number of Ordinary Shares, or a sale of a number of Ordinary Shares k equal to all
or any portion of the number of Ordinary Shares that such Purchaser anticipated receiving from the Company without any restrictive
legend, then, an amount equal to the excess of such Purchaser’s total purchase price (including brokerage commissions and
other out-of-pocket expenses, if any) for the Ordinary Shares so purchased (including brokerage commissions and other out-of-pocket
expenses, if any) (the “Buy-In Price”) over the product of (A) such
number of Shares or Warrant Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied
by (B) the lowest closing sale price of the Ordinary Shares on any Trading Day during the period commencing on the date of the
delivery by such Purchaser to the Company of the applicable Shares or Warrant Shares (as the case may be) and ending on the date
of such delivery and payment under this clause (ii).

 

    28

    

    

 

(e) Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance
with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates
representing Securities as set forth in this Section 4.1 is predicated upon the Company’s reliance upon this understanding.

 

4.2 Furnishing
of Information; Public Information.

 

(a) Until
the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain
the registration of Ordinary Shares under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in
respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof
pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

 

(b) At
any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of
the Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without
restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information
requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future,
and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “Public Information Failure”)
then, in addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an
amount in cash equal to one and one half percent (1.5%) of the aggregate Subscription Amount of such Purchaser’s Securities
held by such Purchaser on the day of a Public Information Failure and on every thirtieth (30th) day (pro rated for periods
totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such
time that such public information is no longer required  for the Purchasers to transfer the Shares and Warrant Shares pursuant
to Rule 144.  The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as
“Public Information Failure Payments.”  Public Information Failure Payments shall be paid on the earlier
of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third
(3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. 
In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure
Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall
limit such Purchaser’s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the
right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief.

 

    29

    

    

 

4.3 Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the
Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior
to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

4.4 Securities
Laws Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b) file a Report on Form 6-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the
Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release,
the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each
Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without
the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser,
with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure
is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public
statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or
include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior
written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement
contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and (b)
to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b).

 

    30

    

    

 

4.5 Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.

 

4.6 Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company, any of its Subsidiaries, or any of their respective officers, director, agents, employees or Affiliates delivers
any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants and agrees
that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective
officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided
that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document
constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Report on Form 6-K. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

4.7 Use
of Proceeds. Except as set forth on Schedule 4.7 attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior
practices), (b) for the redemption of any Ordinary Shares or Ordinary Share Equivalents, (c) for the settlement of any outstanding
litigation or (d) in violation of FCPA or OFAC regulations.

 

    31

    

    

 

4.8 Indemnification
of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any shareholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is solely based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such shareholder or any violations by such
Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined
to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect
of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the
Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a
reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion
of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.
The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected
without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but
only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the
representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.

 

4.9 Reservation
of Ordinary Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of Ordinary Shares for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.

 

    32

    

    

 

4.10 Listing
of Ordinary Shares. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of
the Ordinary Shares on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall
apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the
Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Ordinary Shares
traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take
such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Ordinary Shares on a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Ordinary Shares for electronic
transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely
payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.

 

4.11 Intentionally
omitted.

 

4.12 Subsequent
Equity Sales.

 

(a) From
the date hereof until the 60 days after the Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any Ordinary Shares or Ordinary Share Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, in each case other than (A) as contemplated pursuant to
the Registration Rights Agreement, (B) as contemplated by that (x) certain Amended and Restated Investor Rights Agreement, dated
November 26, 2008, between the Company and the parties signatory thereto, (y) certain Subscription Agreement, dated August 22,
2019 between the Company and the parties signatory thereto, and (z) certain Subscription Agreement, dated December 9, 2019 between
the Company and the parties signatory thereto, (C) a registration statement on Form S-8, and (D) a post-effective amendment to
the registration statement on Form F-1 (333-239576).

 

(b) Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells
any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional
Ordinary Shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies
with, the trading prices of or quotations for the Ordinary Shares at any time after the initial issuance of such debt or equity
securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial
issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Ordinary Shares or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price.
Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall
be in addition to any right to collect damages.

 

    33

    

    

 

4.13 Equal
Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Securities or otherwise.

 

4.14 Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales, of any of the Company’s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4.  Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such
time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release
as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and
the information included in the Disclosure Schedules.  Notwithstanding the foregoing and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company
in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any
duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance
of the initial press release as described in Section 4.4.  Notwithstanding the foregoing, in the case of a Purchaser that
is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

 

4.15 Form
D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser.

 

    34

    

    

 

4.16 Capital
Changes. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward share split
or reclassification of the Ordinary Shares without the prior written consent of the Purchasers holding a majority in interest of
the Shares; provided, however, that no such consent shall be required from Purchasers if the reason for a reverse
share split is to maintain the Company’s listing on the Trading Market.

 

4.17 Acknowledgment
of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding Ordinary
Shares, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations
under the Transaction Documents, including, without limitation, its obligation to issue the Shares and Warrant Shares pursuant
to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction,
regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive
effect that such issuance may have on the ownership of the other shareholders of the Company.

 

4.18 Lock-Up
Agreements. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to
extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms.
If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts
to seek specific performance of the terms of such Lock-Up Agreement.

 

ARTICLE V.

MISCELLANEOUS

 

5.1 Termination. 
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided, however,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

 

5.2 Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company
and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.

 

5.3 Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

    35

    

    

 

5.4 Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto.

 

5.5 Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the
initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted
Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or
a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations
of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in
accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.

 

5.6 Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7 Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the “Purchasers.”

 

5.8 No
Third-Party Beneficiaries. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.

 

    36

    

    

 

5.9 Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.

 

5.10
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

5.11 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

5.12 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

    37

    

    

 

5.13 Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; provided, however, that, in the
case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any Ordinary Shares subject
to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the
Company for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).

 

5.14 Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.

 

5.15 Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

 

5.16 Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

    38

    

    

 

5.17 Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It
is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the
Purchasers.

 

5.18 Liquidated
Damages.  The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.

 

5.19 Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.20 Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and Ordinary Shares in any Transaction Document shall be subject to adjustment for reverse and
forward share splits, share dividends, share combinations and other similar transactions of the Ordinary Shares that occur after
the date of this Agreement.

 

5.21 WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow)

 

    39

    

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	PAINREFORM LTD.	 	Address for Notice:
	 	 	 	 	 
	By:	              	 	Email:
	 	Name:	 	 	 Fax:
	 	Title:	 	 	 

 

	With a copy to (which shall not constitute notice):	 
	 	 	 
	 	 	 
	 	 	 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

    40 

     

    

 

[PURCHASER SIGNATURE PAGES TO PAINREFORM
LTD. SECURITIES PURCHASE AGREEMENT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

Name of Purchaser: ________________________________________________________

 

Signature of Authorized Signatory of
Purchaser: __________________________________

 

Name of Authorized Signatory: ____________________________________________________

 

Title of Authorized Signatory: _____________________________________________________

 

Email Address of Authorized Signatory:
______________________________________________

 

Address for Notice to Purchaser:

 

 

 

Address for Delivery of Securities to Purchaser (if not same
as address for notice):

 

Subscription Amount: $_________________

 

Shares: _________________

 

Warrant Shares: __________________

 

EIN Number: _______________________

 

 

[SIGNATURE PAGES CONTINUE]

 

 

41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]